Separate terms with OR to return results that match either term.
 
Clear All
9,394 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
23155-0774-72 23155-0774 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0775-71 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0775-72 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0776-71 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0776-72 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0777-71 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0777-72 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0778-71 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0778-72 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0779-71 23155-0779 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
43598-0370-74 43598-0370 Pemetrexed disodium Pemetrexed disodium 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0386-62 43598-0386 Pemetrexed disodium Pemetrexed disodium 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0387-11 43598-0387 Pemetrexed disodium Pemetrexed disodium 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0458-04 43598-0458 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 8, 2022 In Use
43598-0458-36 43598-0458 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 8, 2022 In Use
50090-1936-00 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 20, 2015 In Use
50090-1936-01 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 20, 2015 In Use
50090-1936-02 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 25, 2022 In Use
50090-6024-00 50090-6024 Methylprednisolone acetate Methylprednisolone acetate 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Soft Tissue June 27, 2022 In Use
50742-0340-01 50742-0340 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 24, 2022 In Use
50742-0341-01 50742-0341 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 24, 2022 In Use
50742-0484-01 50742-0484 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
50742-0492-01 50742-0492 Carmustine CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea June 25, 2022 In Use
51655-0809-53 51655-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 6, 2022 In Use

Found 9,394 results in 12 milliseconds — Export these results